Fulcrum Therapeutics, Inc.
NASDAQ:FULC
Overview | Financials
Company Name | Fulcrum Therapeutics, Inc. |
Symbol | FULC |
Currency | USD |
Price | 4.55 |
Market Cap | 245,421,085 |
Dividend Yield | 0% |
52-week-range | 2.86 - 13.7 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. Alexander C. Sapir |
Website | https://www.fulcrumtx.com |
An error occurred while fetching data.
About Fulcrum Therapeutics, Inc.
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy; and FTX-6058,
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD